We have one big thing that is booming is the numerous [last data of 15-20 potential patients] patients with mTNBC who want Leronlimab and if efficacy is good with other cancers people will come and Leronlimab will quickly become popular and when combo approval comes we will have revenue immediately. At one point, the scientific and investment public will no longer be able to ignore it.